SCHEMBL20164633

SCHEMBL20164633

CCNc1nc(NC)nc2c(NCCCO)nc(NC)nc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 5/20 0.58
MERTK Q12866 5/20 0.37
FLT3 P36888 3/20 0.37
TYRO3 Q06418 3/20 0.37
GAS6 Q14393 3/20 0.37
AXL P30530 2/20 0.37
TLR8 Q9NR97 1/20 0.35
TLR7 Q9NYK1 1/20 0.35
RAD52 P43351 2/20 0.34
POLB P06746 2/20 0.34
CCNB2 O95067 2/20 0.34
CDK1 P06493 2/20 0.34
CCNB1 P14635 2/20 0.34
CCNB3 Q8WWL7 2/20 0.34
CDK2 P24941 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
KCNH2 Q12809 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL20164454 0.98 SLC29A1 (0.56) SLC29A1MERTKFLT3TYRO3GAS6
SCHEMBL20164523 0.90 SLC29A1 (0.62) SLC29A1MERTKFLT3TYRO3GAS6
Hydrochloric Acid SCHEMBL20164421 0.89 SLC29A1 (0.60) SLC29A1MERTKFLT3TYRO3GAS6
SCHEMBL20164443 0.80 SLC29A1 (0.66) SLC29A1MERTKFLT3TYRO3GAS6
SCHEMBL20164763 0.80 SLC29A1 (0.60) SLC29A1FLT3POLBCCNB2CDK1
Hydrochloric Acid SCHEMBL20164696 0.79 SLC29A1 (0.64) SLC29A1MERTKFLT3TYRO3GAS6
SCHEMBL20164617 0.79 SLC29A1 (0.47) SLC29A1TLR8TLR7RAD52POLB
Hydrochloric Acid SCHEMBL20164519 0.78 SLC29A1 (0.58) SLC29A1FLT3POLBCCNB2CDK1
SCHEMBL16094829 0.77 SLC29A1 (0.71) SLC29A1MERTKFLT3TYRO3GAS6
SCHEMBL16094312 0.77 SLC29A1 (0.51) SLC29A1MERTKTLR7KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250057848-A1 GAL475 COMPOSITIONS AND METHODS OF USE THEREOF NEURIM PHARMACEUTICALS (1991) LTD. (IL) 2025-02-20 US disclosed
EP-3316890-B1 NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME NEURAD LTD (IL) 2023-09-06 EP disclosed
EP-3316890-B1 NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME NEURAD LTD (IL) 2023-09-06 EP disclosed
US-10294228-B2 Breathing control modulating compounds, and methods of making and using same NEURAD LTD. (IL) 2019-05-21 US disclosed
US-10294228-B2 Breathing control modulating compounds, and methods of making and using same NEURAD LTD. (IL) 2019-05-21 US disclosed
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same NEURAD LTD. (IL) 2018-05-24 US disclosed
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same NEURAD LTD. (IL) 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same MTNR1B, CHRM3, PER2 SLC29A1 4472/4885MERTK 4286/4885FLT3 4814/4885
US-20250057848-A1 GAL475 COMPOSITIONS AND METHODS OF USE THEREOF GPR119, GPR35, GPR55 SLC29A1 2077/4885MERTK 4250/4885FLT3 4608/4885
US-10294228-B2 Breathing control modulating compounds, and methods of making and using same MTNR1B, PDE3A, CHRM3 SLC29A1 4518/4885MERTK 4371/4885FLT3 4789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.